Compare AGX & KRYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AGX | KRYS |
|---|---|---|
| Founded | 1961 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Engineering & Construction | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.6B | 7.8B |
| IPO Year | 1995 | 2017 |
| Metric | AGX | KRYS |
|---|---|---|
| Price | $701.29 | $281.57 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 11 |
| Target Price | ★ $409.50 | $297.60 |
| AVG Volume (30 Days) | ★ 233.2K | 215.1K |
| Earning Date | 03-26-2026 | 05-04-2026 |
| Dividend Yield | ★ 0.32% | N/A |
| EPS Growth | 58.37 | ★ 128.00 |
| EPS | ★ 9.74 | 1.83 |
| Revenue | ★ $944,606,000.00 | $389,130,000.00 |
| Revenue This Year | $33.81 | $38.74 |
| Revenue Next Year | $20.97 | $32.53 |
| P/E Ratio | ★ $71.73 | $152.60 |
| Revenue Growth | 8.06 | ★ 33.94 |
| 52 Week Low | $164.00 | $123.03 |
| 52 Week High | $715.98 | $298.30 |
| Indicator | AGX | KRYS |
|---|---|---|
| Relative Strength Index (RSI) | 72.66 | 61.33 |
| Support Level | $258.40 | $254.53 |
| Resistance Level | N/A | $293.60 |
| Average True Range (ATR) | 28.73 | 10.66 |
| MACD | 1.65 | 0.07 |
| Stochastic Oscillator | 86.11 | 98.66 |
Argan Inc is a United States-based construction firm that conducts operations through its wholly-owned subsidiaries, GPS, APC, TRC, and SMC. Through GPS and APC it provides a full range of engineering, procurement, construction, commissioning, maintenance, project development and technical consulting services to the power generation market, including the renewable energy sector, for a wide range of customers, including independent power project owners, public utilities, power plant heavy equipment suppliers and other commercial firms with power requirements in the U.S., Ireland and the U.K. It operates in three segments: Power Services, Industrial Services, and Teledata, out of which Power Services derives the majority of revenue.
Krystal Biotech Inc is engaged in the healthcare sector in the United States. It is focused on the development of easy-to-use, redosable gene therapies to improve the lives of patients living with debilitating diseases. The company used its proprietary gene therapy platform, STAR-D to develop treatments for rare or orphan dermatological indications caused by the absence of or a mutation in a single gene. It plans to leverage its platform to expand its pipeline to include other dermatological indications in the future. The company has one operating segment, which is the business of developing and commercializing pharmaceutical products.